First, an integrated bioinformatics analysis of The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases revealed that ERBB3 was significantly upregulated in both colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ) tissues (p < 0.001, p < 0.0001, Figure 7(A)), and its high expression was significantly associated with shorter overall survival in CRC patients (p < 0.0001, Figure 7(B)). Here, ERBB3 is linked to colorectal carcinoma.